AI-generated summary
The authors report a 24-week, randomized, double-blind, sham-controlled trial of a home-use helmet device emitting 630, 650 and 660 nm light for androgenetic alopecia in 40 enrolled subjects. The LLLT group showed greater hair density and hair diameter than the sham group, and investigator global assessment differed significantly, while subject assessment did not. No serious adverse reactions were detected, and the authors conclude LLLT could be an effective treatment.
- Participants
- 40
- Who or what was studied
- Adults with androgenetic alopecia (men and women) enrolled in a multicenter trial
- Wavelengths
- 630, 650, 660 nm
- Limits stated in the abstract
- The abstract does not report the number of participants per group or the sample size as a limit, and the subject-rated outcome showed no significant difference.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.lww.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Sham device, Sham, Low-level laser therapy, Androgenetic alopecia. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.